Multiple Sclerosis Therapeutics Market 2027 by Types, Application, Technology, Opportunities, End Users and Regions | The Insight Partners

Multiple Sclerosis Therapeutics Market to 2027 - Global Analysis and Forecasts by Drug Class (Immunosuppressant, Immunomodulators); Route of Administration (Injectable, Oral); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, E-Commerce)

Report Code: TIPRE00004057 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
MARKET INTRODUCTION
Multiple sclerosis (MS) is a potentially disabling disease of the central nervous system. In MS, the patient's body immune system attacks the protective sheath (myelin) affecting the nerve fibers and which further lead to communication problems between the brain and the rest of your body. Eventually, the disease can cause permanent damage or deterioration of the nerves. Some people with severe MS may lose the ability to walk independently or at all, numbness or weakness in limbs and others.

MARKET DYNAMICS
The multiple sclerosis therapeutics market is anticipated to grow in the forecast, owing to the factors such as growing research and development for neurology diseases, launch of novel drug candidates and the rising prevalence of multiple sclerosis in children. However, the failure of drugs to prevent disease progression and disability, associated side effects of the drugs such as increased risk of infections, flu-like symptoms and progressive multifocal leukoencephalopathy (PML), are the factors hindering market growth.

MARKET SCOPE
The "Global Multiple Sclerosis Therapeutics Market Analysis to 2027" is a specialized and in-depth study of the pharmaceuticals industry with a special focus on the global market trend analysis. The report aims to provide an overview of multiple sclerosis therapeutics market with detailed market segmentation by drug class, route of administration, distribution channel and geography. The global multiple sclerosis therapeutics market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading multiple sclerosis therapeutics market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION
The global multiple sclerosis therapeutics market is segmented on the basis of drug class, route of administration, distribution channel and geography. Based on drug class, the market is segmented as immunosuppressant and immunomodulators. On the basis of route of administration, the global multiple sclerosis therapeutics market is segmented into injectable and oral. The distribution channel segment is further segmented into hospital pharmacies, retail pharmacies and e-commerce.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global Multiple sclerosis therapeutics market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Multiple sclerosis therapeutics market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting Mmultiple sclerosis therapeutics market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Multiple sclerosis therapeutics market in these regions.

MARKET PLAYERS
The reports cover key developments in the multiple sclerosis therapeutics market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market payers from Mmultiple sclerosis therapeutics market are anticipated to lucrative growth opportunities in the future with the rising demand for multiple sclerosis therapeutics market in the global market. Below mentioned is the list of few companies engaged in the multiple sclerosis therapeutics market.

The report also includes the profiles of key multiple sclerosis therapeutics market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
  • Merck & Co., Inc.
  • Novartis AG
  • Amicus Therapeutics
  • AstraZeneca Plc
  • Boehringer Ingelheim
  • Shire Plc
  • Sanofi Genzyme
  • BioMarin Pharmaceutical, Inc.
  • Horizon Pharma Plc
  • GlaxoSmithKline Plc
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Multiple Sclerosis Therapeutics Market - By Drug Class
1.3.2 Multiple Sclerosis Therapeutics Market - By Route of Administration
1.3.3 Multiple Sclerosis Therapeutics Market - By Distribution Channel
1.3.4 Multiple Sclerosis Therapeutics Market - By Region
1.3.4.1 By Country
2. KEY TAKEWAYS
3. RESEARCH METHODOLOGY
4. MULTIPLE SCLEROSIS THERAPEUTICS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. MULTIPLE SCLEROSIS THERAPEUTICS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. MULTIPLE SCLEROSIS THERAPEUTICS MARKET - GLOBAL MARKET ANALYSIS
6.1. MULTIPLE SCLEROSIS THERAPEUTICS - GLOBAL MARKET OVERVIEW
6.2. MULTIPLE SCLEROSIS THERAPEUTICS - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. MULTIPLE SCLEROSIS THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2027 - DRUG CLASS
7.1. OVERVIEW
7.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
7.3. IMMUNOSUPPRESSANT
7.3.1. Overview
7.3.2. Immunosuppressant Market Forecast and Analysis
7.4. IMMUNOMODULATORS
7.4.1. Overview
7.4.2. Immunomodulators Market Forecast and Analysis
8. MULTIPLE SCLEROSIS THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2027 - ROUTE OF ADMINISTRATION
8.1. OVERVIEW
8.2. ROUTE OF ADMINISTRATION MARKET FORECASTS AND ANALYSIS
8.3. INJECTABLE
8.3.1. Overview
8.3.2. Injectable Market Forecast and Analysis
8.4. ORAL
8.4.1. Overview
8.4.2. Oral Market Forecast and Analysis
9. MULTIPLE SCLEROSIS THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2027 - DISTRIBUTION CHANNEL
9.1. OVERVIEW
9.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
9.3. HOSPITAL PHARMACIES
9.3.1. Overview
9.3.2. Hospital Pharmacies Market Forecast and Analysis
9.4. RETAIL PHARMACIES
9.4.1. Overview
9.4.2. Retail Pharmacies Market Forecast and Analysis
9.5. E-COMMERCE
9.5.1. Overview
9.5.2. E-Commerce Market Forecast and Analysis
10. MULTIPLE SCLEROSIS THERAPEUTICS MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Multiple Sclerosis Therapeutics Market Overview
10.1.2 North America Multiple Sclerosis Therapeutics Market Forecasts and Analysis
10.1.3 North America Multiple Sclerosis Therapeutics Market Forecasts and Analysis - By Drug Class
10.1.4 North America Multiple Sclerosis Therapeutics Market Forecasts and Analysis - By Route of Administration
10.1.5 North America Multiple Sclerosis Therapeutics Market Forecasts and Analysis - By Distribution Channel
10.1.6 North America Multiple Sclerosis Therapeutics Market Forecasts and Analysis - By Countries
10.1.6.1 United States Multiple Sclerosis Therapeutics Market
10.1.6.1.1 United States Multiple Sclerosis Therapeutics Market by Drug Class
10.1.6.1.2 United States Multiple Sclerosis Therapeutics Market by Route of Administration
10.1.6.1.3 United States Multiple Sclerosis Therapeutics Market by Distribution Channel
10.1.6.2 Canada Multiple Sclerosis Therapeutics Market
10.1.6.2.1 Canada Multiple Sclerosis Therapeutics Market by Drug Class
10.1.6.2.2 Canada Multiple Sclerosis Therapeutics Market by Route of Administration
10.1.6.2.3 Canada Multiple Sclerosis Therapeutics Market by Distribution Channel
10.1.6.3 Mexico Multiple Sclerosis Therapeutics Market
10.1.6.3.1 Mexico Multiple Sclerosis Therapeutics Market by Drug Class
10.1.6.3.2 Mexico Multiple Sclerosis Therapeutics Market by Route of Administration
10.1.6.3.3 Mexico Multiple Sclerosis Therapeutics Market by Distribution Channel
10.2. EUROPE
10.2.1 Europe Multiple Sclerosis Therapeutics Market Overview
10.2.2 Europe Multiple Sclerosis Therapeutics Market Forecasts and Analysis
10.2.3 Europe Multiple Sclerosis Therapeutics Market Forecasts and Analysis - By Drug Class
10.2.4 Europe Multiple Sclerosis Therapeutics Market Forecasts and Analysis - By Route of Administration
10.2.5 Europe Multiple Sclerosis Therapeutics Market Forecasts and Analysis - By Distribution Channel
10.2.6 Europe Multiple Sclerosis Therapeutics Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Multiple Sclerosis Therapeutics Market
10.2.6.1.1 Germany Multiple Sclerosis Therapeutics Market by Drug Class
10.2.6.1.2 Germany Multiple Sclerosis Therapeutics Market by Route of Administration
10.2.6.1.3 Germany Multiple Sclerosis Therapeutics Market by Distribution Channel
10.2.6.2 France Multiple Sclerosis Therapeutics Market
10.2.6.2.1 France Multiple Sclerosis Therapeutics Market by Drug Class
10.2.6.2.2 France Multiple Sclerosis Therapeutics Market by Route of Administration
10.2.6.2.3 France Multiple Sclerosis Therapeutics Market by Distribution Channel
10.2.6.3 Italy Multiple Sclerosis Therapeutics Market
10.2.6.3.1 Italy Multiple Sclerosis Therapeutics Market by Drug Class
10.2.6.3.2 Italy Multiple Sclerosis Therapeutics Market by Route of Administration
10.2.6.3.3 Italy Multiple Sclerosis Therapeutics Market by Distribution Channel
10.2.6.4 Spain Multiple Sclerosis Therapeutics Market
10.2.6.4.1 Spain Multiple Sclerosis Therapeutics Market by Drug Class
10.2.6.4.2 Spain Multiple Sclerosis Therapeutics Market by Route of Administration
10.2.6.4.3 Spain Multiple Sclerosis Therapeutics Market by Distribution Channel
10.2.6.5 United Kingdom Multiple Sclerosis Therapeutics Market
10.2.6.5.1 United Kingdom Multiple Sclerosis Therapeutics Market by Drug Class
10.2.6.5.2 United Kingdom Multiple Sclerosis Therapeutics Market by Route of Administration
10.2.6.5.3 United Kingdom Multiple Sclerosis Therapeutics Market by Distribution Channel
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Multiple Sclerosis Therapeutics Market Overview
10.3.2 Asia-Pacific Multiple Sclerosis Therapeutics Market Forecasts and Analysis
10.3.3 Asia-Pacific Multiple Sclerosis Therapeutics Market Forecasts and Analysis - By Drug Class
10.3.4 Asia-Pacific Multiple Sclerosis Therapeutics Market Forecasts and Analysis - By Route of Administration
10.3.5 Asia-Pacific Multiple Sclerosis Therapeutics Market Forecasts and Analysis - By Distribution Channel
10.3.6 Asia-Pacific Multiple Sclerosis Therapeutics Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Multiple Sclerosis Therapeutics Market
10.3.6.1.1 Australia Multiple Sclerosis Therapeutics Market by Drug Class
10.3.6.1.2 Australia Multiple Sclerosis Therapeutics Market by Route of Administration
10.3.6.1.3 Australia Multiple Sclerosis Therapeutics Market by Distribution Channel
10.3.6.2 China Multiple Sclerosis Therapeutics Market
10.3.6.2.1 China Multiple Sclerosis Therapeutics Market by Drug Class
10.3.6.2.2 China Multiple Sclerosis Therapeutics Market by Route of Administration
10.3.6.2.3 China Multiple Sclerosis Therapeutics Market by Distribution Channel
10.3.6.3 India Multiple Sclerosis Therapeutics Market
10.3.6.3.1 India Multiple Sclerosis Therapeutics Market by Drug Class
10.3.6.3.2 India Multiple Sclerosis Therapeutics Market by Route of Administration
10.3.6.3.3 India Multiple Sclerosis Therapeutics Market by Distribution Channel
10.3.6.4 Japan Multiple Sclerosis Therapeutics Market
10.3.6.4.1 Japan Multiple Sclerosis Therapeutics Market by Drug Class
10.3.6.4.2 Japan Multiple Sclerosis Therapeutics Market by Route of Administration
10.3.6.4.3 Japan Multiple Sclerosis Therapeutics Market by Distribution Channel
10.3.6.5 South Korea Multiple Sclerosis Therapeutics Market
10.3.6.5.1 South Korea Multiple Sclerosis Therapeutics Market by Drug Class
10.3.6.5.2 South Korea Multiple Sclerosis Therapeutics Market by Route of Administration
10.3.6.5.3 South Korea Multiple Sclerosis Therapeutics Market by Distribution Channel
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Multiple Sclerosis Therapeutics Market Overview
10.4.2 Middle East and Africa Multiple Sclerosis Therapeutics Market Forecasts and Analysis
10.4.3 Middle East and Africa Multiple Sclerosis Therapeutics Market Forecasts and Analysis - By Drug Class
10.4.4 Middle East and Africa Multiple Sclerosis Therapeutics Market Forecasts and Analysis - By Route of Administration
10.4.5 Middle East and Africa Multiple Sclerosis Therapeutics Market Forecasts and Analysis - By Distribution Channel
10.4.6 Middle East and Africa Multiple Sclerosis Therapeutics Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Multiple Sclerosis Therapeutics Market
10.4.6.1.1 South Africa Multiple Sclerosis Therapeutics Market by Drug Class
10.4.6.1.2 South Africa Multiple Sclerosis Therapeutics Market by Route of Administration
10.4.6.1.3 South Africa Multiple Sclerosis Therapeutics Market by Distribution Channel
10.4.6.2 Saudi Arabia Multiple Sclerosis Therapeutics Market
10.4.6.2.1 Saudi Arabia Multiple Sclerosis Therapeutics Market by Drug Class
10.4.6.2.2 Saudi Arabia Multiple Sclerosis Therapeutics Market by Route of Administration
10.4.6.2.3 Saudi Arabia Multiple Sclerosis Therapeutics Market by Distribution Channel
10.4.6.3 U.A.E Multiple Sclerosis Therapeutics Market
10.4.6.3.1 U.A.E Multiple Sclerosis Therapeutics Market by Drug Class
10.4.6.3.2 U.A.E Multiple Sclerosis Therapeutics Market by Route of Administration
10.4.6.3.3 U.A.E Multiple Sclerosis Therapeutics Market by Distribution Channel
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Multiple Sclerosis Therapeutics Market Overview
10.5.2 South and Central America Multiple Sclerosis Therapeutics Market Forecasts and Analysis
10.5.3 South and Central America Multiple Sclerosis Therapeutics Market Forecasts and Analysis - By Drug Class
10.5.4 South and Central America Multiple Sclerosis Therapeutics Market Forecasts and Analysis - By Route of Administration
10.5.5 South and Central America Multiple Sclerosis Therapeutics Market Forecasts and Analysis - By Distribution Channel
10.5.6 South and Central America Multiple Sclerosis Therapeutics Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Multiple Sclerosis Therapeutics Market
10.5.6.1.1 Brazil Multiple Sclerosis Therapeutics Market by Drug Class
10.5.6.1.2 Brazil Multiple Sclerosis Therapeutics Market by Route of Administration
10.5.6.1.3 Brazil Multiple Sclerosis Therapeutics Market by Distribution Channel
10.5.6.2 Argentina Multiple Sclerosis Therapeutics Market
10.5.6.2.1 Argentina Multiple Sclerosis Therapeutics Market by Drug Class
10.5.6.2.2 Argentina Multiple Sclerosis Therapeutics Market by Route of Administration
10.5.6.2.3 Argentina Multiple Sclerosis Therapeutics Market by Distribution Channel
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. MULTIPLE SCLEROSIS THERAPEUTICS MARKET, KEY COMPANY PROFILES
12.1. NOVARTIS AG
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. TEVA PHARMACEUTICALS INDUSTRIES LTD.
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. SANOFI GENZYME
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. BAYER AG
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. PFIZER, INC.
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. BIOGEN IDEC
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. MERCK AND CO., INC.
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. ABBVIE, INC.
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. ALKERMES
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. MAPI-PHARMA LTD.
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
The List of Companies

1. Novartis AG
2. Teva Pharmaceuticals Industries Ltd.
3. Sanofi Genzyme
4. Bayer AG
5. Pfizer, Inc.
6. Biogen Idec
7. Merck and Co., Inc
8. Abbvie, Inc.
9. Alkermes
10. Mapi-pharma Ltd.